385 related articles for article (PubMed ID: 16434471)
1. Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15.
Okumura A; Lu G; Pitha-Rowe I; Pitha PM
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1440-5. PubMed ID: 16434471
[TBL] [Abstract][Full Text] [Related]
2. Tsg101, an inactive homologue of ubiquitin ligase e2, interacts specifically with human immunodeficiency virus type 2 gag polyprotein and results in increased levels of ubiquitinated gag.
Myers EL; Allen JF
J Virol; 2002 Nov; 76(22):11226-35. PubMed ID: 12388682
[TBL] [Abstract][Full Text] [Related]
3. Defects in human immunodeficiency virus budding and endosomal sorting induced by TSG101 overexpression.
Goila-Gaur R; Demirov DG; Orenstein JM; Ono A; Freed EO
J Virol; 2003 Jun; 77(11):6507-19. PubMed ID: 12743307
[TBL] [Abstract][Full Text] [Related]
4. Nedd4.1-mediated ubiquitination and subsequent recruitment of Tsg101 ensure HTLV-1 Gag trafficking towards the multivesicular body pathway prior to virus budding.
Blot V; Perugi F; Gay B; Prévost MC; Briant L; Tangy F; Abriel H; Staub O; Dokhélar MC; Pique C
J Cell Sci; 2004 May; 117(Pt 11):2357-67. PubMed ID: 15126635
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 Vpr Abrogates the Effect of TSG101 Overexpression to Support Virus Release.
Chutiwitoonchai N; Siarot L; Takeda E; Shioda T; Ueda M; Aida Y
PLoS One; 2016; 11(9):e0163100. PubMed ID: 27648839
[TBL] [Abstract][Full Text] [Related]
6. The functionally exchangeable L domains in RSV and HIV-1 Gag direct particle release through pathways linked by Tsg101.
Medina G; Zhang Y; Tang Y; Gottwein E; Vana ML; Bouamr F; Leis J; Carter CA
Traffic; 2005 Oct; 6(10):880-94. PubMed ID: 16138902
[TBL] [Abstract][Full Text] [Related]
7. HIV Gag mimics the Tsg101-recruiting activity of the human Hrs protein.
Pornillos O; Higginson DS; Stray KM; Fisher RD; Garrus JE; Payne M; He GP; Wang HE; Morham SG; Sundquist WI
J Cell Biol; 2003 Aug; 162(3):425-34. PubMed ID: 12900394
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function.
Demirov DG; Ono A; Orenstein JM; Freed EO
Proc Natl Acad Sci U S A; 2002 Jan; 99(2):955-60. PubMed ID: 11805336
[TBL] [Abstract][Full Text] [Related]
9. Tsg101 control of human immunodeficiency virus type 1 Gag trafficking and release.
Goff A; Ehrlich LS; Cohen SN; Carter CA
J Virol; 2003 Sep; 77(17):9173-82. PubMed ID: 12915533
[TBL] [Abstract][Full Text] [Related]
10. Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag).
VerPlank L; Bouamr F; LaGrassa TJ; Agresta B; Kikonyogo A; Leis J; Carter CA
Proc Natl Acad Sci U S A; 2001 Jul; 98(14):7724-9. PubMed ID: 11427703
[TBL] [Abstract][Full Text] [Related]
11. ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity.
Okumura A; Pitha PM; Harty RN
Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3974-9. PubMed ID: 18305167
[TBL] [Abstract][Full Text] [Related]
12. ISG15 enhances the innate antiviral response by inhibition of IRF-3 degradation.
Lu G; Reinert JT; Pitha-Rowe I; Okumura A; Kellum M; Knobeloch KP; Hassel B; Pitha PM
Cell Mol Biol (Noisy-le-grand); 2006 May; 52(1):29-41. PubMed ID: 16914094
[TBL] [Abstract][Full Text] [Related]
13. The interferon-induced gene ISG15 blocks retrovirus release from cells late in the budding process.
Pincetic A; Kuang Z; Seo EJ; Leis J
J Virol; 2010 May; 84(9):4725-36. PubMed ID: 20164219
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress.
Martin-Serrano J; Zang T; Bieniasz PD
Nat Med; 2001 Dec; 7(12):1313-9. PubMed ID: 11726971
[TBL] [Abstract][Full Text] [Related]
15. The C-terminal half of TSG101 blocks Rous sarcoma virus budding and sequesters Gag into unique nonendosomal structures.
Johnson MC; Spidel JL; Ako-Adjei D; Wills JW; Vogt VM
J Virol; 2005 Mar; 79(6):3775-86. PubMed ID: 15731271
[TBL] [Abstract][Full Text] [Related]
16. Interferon-induced ISG15 conjugation inhibits influenza A virus gene expression and replication in human cells.
Hsiang TY; Zhao C; Krug RM
J Virol; 2009 Jun; 83(12):5971-7. PubMed ID: 19357168
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HIV budding by a genetically selected cyclic peptide targeting the Gag-TSG101 interaction.
Tavassoli A; Lu Q; Gam J; Pan H; Benkovic SJ; Cohen SN
ACS Chem Biol; 2008 Dec; 3(12):757-64. PubMed ID: 19053244
[TBL] [Abstract][Full Text] [Related]
18. Interferon-mediated ISG15 conjugation restricts dengue virus 2 replication.
Hishiki T; Han Q; Arimoto K; Shimotohno K; Igarashi T; Vasudevan SG; Suzuki Y; Yamamoto N
Biochem Biophys Res Commun; 2014 May; 448(1):95-100. PubMed ID: 24769207
[TBL] [Abstract][Full Text] [Related]
19. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment.
Chen L; Sun J; Meng L; Heathcote J; Edwards AM; McGilvray ID
J Gen Virol; 2010 Feb; 91(Pt 2):382-8. PubMed ID: 19846672
[TBL] [Abstract][Full Text] [Related]
20. TSG101 interaction with HRS mediates endosomal trafficking and receptor down-regulation.
Lu Q; Hope LW; Brasch M; Reinhard C; Cohen SN
Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7626-31. PubMed ID: 12802020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
